MOH — authorised 14 December 1990
- Marketing authorisation holder: FOUGERA PHARMS
- Status: likely_approved
MOH authorised Cutivate on 14 December 1990
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 14 December 1990.
FOUGERA PHARMS holds the Israeli marketing authorisation.